| Cetuximab for the treatment of colorectal cancer DJ Jonker, CJ O'Callaghan, CS Karapetis, JR Zalcberg, D Tu, HJ Au, ... New England Journal of Medicine 357 (20), 2040-2048, 2007 | 2433 | 2007 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1144 | 2018 |
| Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ... Jama 317 (23), 2392-2401, 2017 | 829 | 2017 |
| Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study E Van Cutsem, F Rivera, S Berry, A Kretzschmar, M Michael, ... Annals of Oncology 20 (11), 1842-1847, 2009 | 701 | 2009 |
| American society of clinical oncology statement: toward individualized care for patients with advanced cancer JM Peppercorn, TJ Smith, PR Helft, DJ DeBono, SR Berry, DS Wollins, ... J Clin Oncol 29 (6), 755-760, 2011 | 613 | 2011 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 473 | 2021 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 445 | 2019 |
| Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO. 26 Study EX Chen, DJ Jonker, JM Loree, HF Kennecke, SR Berry, F Couture, ... JAMA oncology 6 (6), 831-838, 2020 | 276 | 2020 |
| Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group CM Canil, MJ Moore, E Winquist, T Baetz, M Pollak, KN Chi, S Berry, ... Journal of Clinical Oncology 23 (3), 455-460, 2005 | 243 | 2005 |
| Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 191 | 2021 |
| Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up E Van Cutsem, J Oliveira Annals of Oncology 20, iv49-iv50, 2009 | 154 | 2009 |
| Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate … F Saad, S Hotte, S North, B Eigl, K Chi, P Czaykowski, L Wood, M Pollak, ... Clinical Cancer Research 17 (17), 5765-5773, 2011 | 142 | 2011 |
| Association between prognosis and tumor laterality in early-stage colon cancer S Karim, K Brennan, S Nanji, SR Berry, CM Booth JAMA oncology 3 (10), 1386-1392, 2017 | 102 | 2017 |
| Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial H Kennecke, S Berry, R Wong, C Zhou, K Tankel, J Easaw, S Rao, J Post, ... European Journal of Cancer 48 (1), 37-45, 2012 | 97 | 2012 |
| Continental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs SR Berry, CM Bell, PA Ubel, WK Evans, E Nadler, EL Strevel, ... Journal of Clinical Oncology 28 (27), 4149-4153, 2010 | 87 | 2010 |
| Clinically important aspects of lymph node assessment in colon cancer FC Wright, CHL Law, S Berry, AJ Smith Journal of surgical oncology 99 (4), 248-255, 2009 | 85 | 2009 |
| Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis KKW Chan, H Guo, S Cheng, JM Beca, R Redmond‐Misner, ... Cancer medicine 9 (1), 160-169, 2020 | 81 | 2020 |
| A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis ABK Abrahao, YJ Ko, S Berry, KKW Chan Clinical Colorectal Cancer 17 (2), 113-120, 2018 | 76 | 2018 |
| Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's … E Winquist, T Waldron, S Berry, DS Ernst, S Hotte, H Lukka BMC cancer 6, 1-18, 2006 | 72 | 2006 |
| Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma RC Grant, R Denroche, GH Jang, KM Nowak, A Zhang, A Borgida, ... Gut 70 (10), 1894-1903, 2021 | 66 | 2021 |
